RxDoctor Payments Data

Maureen Leehey

Neurology · Aurora, CONPI 1336258714

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $393 of the $606 with a category attached, or 64.8%. Sentynl Therapeutics, Inc. accounts for 64.8% of it on its own, with 2 other manufacturers making up the rest. Reporting peaked in 2019 at $563 and has fallen 99.9% since, to $1 in 2022. That places this record below the midpoint for neurology clinicians in CO, where the typical reported total is $699.

$606in general payments, 2019–2025

Across 6 payments — averaging $101.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sentynl Therapeutics, Inc.$393
  • Neurocrine Biosciences, Inc.$212
  • Travere Therapeutics, Inc.$1
$1,111,564in research payments, 2019–2025

Across 29 payments — averaging $38,330 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Biogen$920K
  • Mallinckrodt Hospital Products Inc.$86K
  • MDD US Operations, LLC$65K
  • Mallinckrodt Enterprises LLC$40K

What the payments were for

  • Consulting fees$39365%
  • Food & beverage$21235%
  • Education$10%

General payments by program year

19
21
22

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Sentynl Therapeutics, Inc.1$393
Neurocrine Biosciences, Inc.4$212
Travere Therapeutics, Inc.1$1

How this compares

$606 in reported general payments places this provider in the 45th percentile of 334 neurology providers in Colorado.

See all neurology providers in Colorado →

Other neurology in Aurora

See the full list for Colorado →

Where these figures come from

Is this you, or does something look wrong? →